Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; School of Clinical Medicine, University of Cambridge, Cambridge CB2 0SP, UK.
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Resphera Biosciences, Baltimore, MD 21231, USA.
Cell. 2019 Jul 25;178(3):518-520. doi: 10.1016/j.cell.2019.07.005.
Although serial tumor assessments are increasingly performed through imaging and molecular approaches, such evaluations are often considered in isolation, as robust frameworks for integrating multiple biomarkers are currently lacking. Thus, in this issue of Cell, Kurtz et al. present a method (termed CIRI) that integrates pre-treatment and on-treatment risk factors for accurate outcome prediction.
虽然通过影像学和分子方法越来越多地进行连续肿瘤评估，但由于目前缺乏整合多种生物标志物的稳健框架，此类评估通常被孤立考虑。因此，在本期《细胞》杂志上，Kurtz 等人提出了一种方法（称为 CIRI），该方法可整合治疗前和治疗中的风险因素，以实现准确的预后预测。
